Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Expanded Access Program in BRCA-mutated Platinum-sensitive Relapsed High-grade Epithelial Ovarian Cancer (Japan)
jRCT2080223485Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Started Mar 2017; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on jRCT2080223485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223485.